Difference between revisions of "Endometrial carcinoma"
Jump to navigation
Jump to search
m (→Management) |
|||
| Line 43: | Line 43: | ||
|- | |- | ||
|Clinical <br>characteristics | |Clinical <br>characteristics | ||
| | | premenopausal, estrogen excess, obesity | ||
| postmenopausal, no estrogen excess, atrophic endometrium | | postmenopausal, no estrogen excess, atrophic endometrium | ||
|- | |- | ||
| Line 53: | Line 53: | ||
| microsatellite instability, PTEN & KRAS mutations | | microsatellite instability, PTEN & KRAS mutations | ||
| p53 mutations | | p53 mutations | ||
|- | |||
|Precursor lesion(s) | |||
| [[endometrial hyperplasia]] | |||
| possibly ''endometrial intraepithelial carcinoma''<ref name=pmid22249577>{{Cite journal | last1 = Roelofsen | first1 = T. | last2 = van Kempen | first2 = LC. | last3 = van der Laak | first3 = JA. | last4 = van Ham | first4 = MA. | last5 = Bulten | first5 = J. | last6 = Massuger | first6 = LF. | title = Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? | journal = Int J Gynecol Cancer | volume = 22 | issue = 3 | pages = 457-64 | month = Mar | year = 2012 | doi = 10.1097/IGC.0b013e3182434a81 | PMID = 22249577 }}</ref> | |||
|} | |} | ||